Lifting weights preserved muscle during tirzepatide weight loss in a trial
In 120 adults losing about 22 kg on tirzepatide, adding thrice-weekly resistance training spared roughly 1 kg of lean mass and turned strength loss into strength gain. Fat loss was unchanged.
| Group | Value (kg) |
|---|---|
| Total lean — tirzepatide only | 4.67 |
| Total lean — tirzepatide + exercise | 3.57 |
| Appendicular lean — tirzepatide only | 3.55 |
| Appendicular lean — tirzepatide + exercise | 2.92 |
Adding a structured weights programme to tirzepatide protected muscle without blunting the drug's weight loss, in a randomised trial published in Nature Medicine [s1]. The finding speaks to a known downside of the powerful new obesity drugs: a large share of the weight they strip off is not fat but lean soft tissue, including muscle. The trial is modest in size and ran for 40 weeks, but it tested the obvious countermeasure head-on and it worked.
The problem the trial addresses
Drugs such as tirzepatide produce weight loss that was until recently achievable only with surgery. But the body sheds muscle as well as fat when it loses weight quickly, and muscle matters for strength, metabolism and — especially in older people — independence. The open question has been practical: can resistance exercise, done alongside the drug, keep that muscle, and does it cost anything in fat loss? This trial set out to answer exactly that.
What the trial did
The researchers ran a two-arm randomised controlled trial in 120 adults with overweight or obesity [s1]. Every participant was treated with tirzepatide, and most tolerated up-titration to the 15 mg weekly dose [s1]. They were then randomised either to thrice-weekly resistance-exercise training or to usual activities, for 40 weeks [s1]. Adherence to the exercise programme was high, at 91% [s1]. The trial is registered as ACTRN12623001236684 [s1].
Body composition was measured directly rather than by weight alone. The primary outcomes were the change in total fat mass and the change in total lean soft tissue mass [s1].
What it found
The weight loss itself was essentially identical in the two groups — a mean of 22.61 kg on tirzepatide alone and 22.28 kg with added exercise (p=0.694) [s1]. Fat loss was also the same: 17.19 kg versus 17.98 kg, with a between-group difference of −0.77 kg (95% CI −2.14 to 0.60) that was not significant [s1]. In other words, lifting weights did not cost participants any of the drug's fat-burning benefit.
Where the groups diverged was muscle. Total lean soft tissue mass fell by 4.67 kg on the drug alone but by only 3.57 kg with added exercise — a difference of 1.09 kg (95% CI 0.43 to 1.75, p<0.001) [s1]. The same pattern held for appendicular lean mass, the muscle of the arms and legs: a 3.55 kg loss on the drug alone versus 2.92 kg with exercise (p<0.001) [s1].
Strength moved in opposite directions. On tirzepatide alone, participants got weaker: bench press fell by 4.09 kg, lat pulldown by 4.42 kg and knee extension by 4.42 kg [s1]. With added resistance training, the same measures rose — by 4.68 kg, 8.58 kg and 5.88 kg respectively, each significantly better than the drug-only arm (all p<0.001) [s1].
How to read it
The result is clean, but keep its size in view. This was 120 people over 40 weeks; it shows that exercise spares muscle and builds strength during drug-induced weight loss, not how much that translates into fewer falls, better metabolic health or longer independence — outcomes a trial this length cannot capture. The lean-mass saving, about 1 kg, is real and statistically clear but modest against a roughly 22 kg total loss, so resistance training reshapes the composition of the loss more than its amount. And the participants were a motivated, high-adherence group; 91% adherence to thrice-weekly training is not what most people achieve outside a trial.
The strength findings are arguably the more striking half: people kept losing weight at full tilt while getting stronger, which is the opposite of what happens with the drug alone. That matters because strength, not scale weight, is what the muscle-loss worry is ultimately about.
What to watch
The questions now are whether the muscle and strength gains persist after the trial and after the drug is stopped, how much training is the minimum that works, and whether sparing lean mass changes the outcomes that matter over years rather than weeks. For now, the honest summary is that resistance exercise was an effective add-on to tirzepatide — protecting muscle and improving strength at no cost to fat loss — in a single well-run trial [s1].
This article describes clinical-trial results and is not medical advice. Anyone taking a weight-loss drug should discuss exercise and nutrition with their own clinician.
Sources
- Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial — Nature Medicine , November 9, 2026
More on
Tirzepatide cut BMI by about 18% in adolescents with obesity in a phase 3 trial
In SURMOUNT-ADOLESCENTS, 160 teenagers were randomised to the weekly injection or placebo for 72 weeks. It is a BMI result in a single drug-company-funded trial, not an outcomes study.
Tirzepatide beat semaglutide head to head for weight loss in SURMOUNT-5
The first randomised head-to-head trial of the two obesity drugs gave 751 adults the maximum tolerated dose of each for 72 weeks. Tirzepatide cut weight by 20.2%, semaglutide by 13.7%.
Mazdutide cut body weight by about 17% in a phase 3 obesity trial in China
GLORY-2 randomised 461 Chinese adults with obesity to a weekly GLP-1/glucagon dual agonist or placebo; weight fell 16.65% versus 1.50% at 60 weeks, alongside high rates of nausea and vomiting.
Mazdutide cut weight by 18% at its top dose in a first US obesity trial
The glucagon and GLP-1 dual agonist, already approved in China, cut bodyweight 18.1% at 16 mg and 15.6% at 10 mg over 32 weeks versus 0.9% on placebo in a US phase 2 trial.